What Is the First-Line Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease?
Clinical Context
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition in which excess fat accumulates in the liver in association with metabolic risk factors. The first-line approach is evidence-based and targets modifiable lifestyle contributors, with specific considerations depending on the patient's weight status and degree of hepatic fibrosis.
Treatment Approach — Partial Overview
First-line management centres on a structured liver-protective lifestyle intervention involving dietary changes and increased physical activity, with additional behavioural guidance specific to patients with more advanced hepatic involvement. The full protocol details the complete, individualised approach.
Clinical Goals
Weight loss of 3%–5% improves hepatic steatosis, while weight loss greater than 10% is generally required to improve NASH and fibrosis.
References
DOI: 10.1097/HEP.0000000000000323
- A healthy diet and regular exercise form the foundation of treatment for the vast majority of those with NAFLD.
- Patients with NAFLD who are overweight or obese should be prescribed a diet that leads to a caloric deficit. When possible, diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (e.g., Mediterranean diet) should be encouraged due to their additional cardiovascular benefits.
- Patients with NAFLD should be strongly encouraged to increase their activity level to the extent possible. Individualized prescriptive exercise recommendations may increase sustainability and have benefits independent of weight loss.
- Some studies demonstrate that regular moderate exercise at least 5 times per week for a total of 150 minutes per week or an increase in activity level by more than 60 minutes per week can prevent or improve NAFLD.
- Drinking 3 or more cups per day could be recommended in the absence of contraindications based on the reduced risk for NAFLD and liver fibrosis demonstrated in epidemiological studies and meta-analyses.
- Patients with clinically significant hepatic fibrosis (≥F2) should abstain from alcohol use completely.
- Weight loss of 3%–5% improves steatosis, but greater weight loss (>10%) is generally required to improve NASH and fibrosis.
View source ↗